Neuroleptic Malignant Syndrome in an Adolescent After Brief Exposure to Olanzapine

Hanft, Alan; Eggleston, Christopher; Bourgeois, James A.

doi:10.1089/1044546042389235

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There may be other explanations with respect to risperidone‐induced increases in REE and TEE. The activity of skeletal muscle may contribute to the increased energy expenditure, as AAD treatment results in increased muscle tone in patients and rats . Moreover, the automatic nervous system is deeply involved in the regulation of energy metabolism, and one study indicated that AADs induce instability in the automatic nervous system , which may increase firing rates of sympathetic nerves leading to increased energy expenditure .…”

Section: Discussionmentioning

confidence: 99%

Effects of risperidone on energy balance in female C57BL/6J mice

Johnson

Smith

et al. 2013

Obesity

View full text Add to dashboard Cite

Objective To investigate the effect of risperidone on energy expenditure and weight gain in female C57BL/6J mice. Design and Methods Body weight and composition, food intake, energy expenditure, and activity were determined weekly. mRNA expression of uncoupling protein 1 in brown adipose tissue, orexin and brain-derived neurotrophic factor in the hypothalamus were quantified by Real-Time PCR. Results Risperidone tended to induce a greater body weight gain (P=0.052) and significantly higher food intake (P=0.038) relative to the placebo-treated group. Risperidone-treated mice had a higher resting energy expenditure (P=0.001), and total energy expenditure (P=0.005) than the placebo group. There were no effects of treatment, time, and treatment by time on NREE between groups. Risperidone-treated mice showed a significantly lesser locomotor activity than placebo-treated mice over 3 weeks (P<0.001). Risperidone induced a higher UCP1 mRNA (P=0.003) and a lower orexin mRNA (P=0.001) than placebo. Discussion Risperidone-induced weight gain is associated with hyperphagia and a reduction in locomotor activity in C57BL/6J mice. Additionally, higher total and resting energy expenditure were accompanied by higher levels of UCP1 mRNA in BAT. The increased total energy expenditure could not offset the total intake of energy through risperidone-induced hyperphagia, therefore resulting in weight gain in female C57BL/6J mice.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of risperidone on energy balance in female C57BL/6J mice

Johnson

Smith

et al. 2013

Obesity

View full text Add to dashboard Cite

show abstract

“…The rare occurrence of NMS cases in childhood could be due to the less frequent neuroleptic drug use in this age group (12). However, case reports of NMS development in children and adolescents following the use of drugs such as olanzapine, quetiapine, ziprasidone, risperidone, and alimemazine have increased in recent years (4,(13)(14)(15)(16)(17). We present a 2.5-year-old case who developed NMS following a single dose of risperidone as it is the youngest reported case to the best of our knowledge.…”

Section: Introductionmentioning

confidence: 99%

Neuroleptic Malignant Syndrome Due to Risperidone Overdose in a Child: A Case Report

Saltık

Başgül

2012

Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychophar

View full text Add to dashboard Cite

Bir çocukta risperidon aşırı dozuna bağlı gelişen nöroleptik malign sendrom: Bir olgu sunumu Nöroleptik malign sendrom, nadir görülen ancak ölümcül olabilen, antipsikotik ilaçlara karşı gelişen idiosenkrazik bir reaksiyondur. Bu sendrom hipertermi, kas rijiditesi, akinezi, şuur değişikliği, otonomik disfonksiyon, yüksek kreatinin kinaz seviyesi, lökositoz ile karakterizedir. Bu yazıda, risperidona bağlı nöroleptik malign sendrom gelişen, 2,5 yaşındaki erkek olgu, literatürdeki en küçük olgu olması nedeniyle sunulmuştur.

show abstract

“…3. Eighteen VigiBase ICSRs were included in the critical review of ICSRs, excluding the two overlapping published case reports in the RM group as well as two ICSRs in the RM + NMS group that originated from the literature (Hanft et al 2004;Watson et al 2004).…”

Section: Resultsmentioning

confidence: 99%

“…Number and Type of Reports Included in Each Part of the Analysis of Rhabdomyolysis Co-Reported With and Without Neuroleptic Malignant Syndrome (NMS) for Children and Adolescents Taking Antipsychotic Medicines, by VigiBase Individual Case Safety Reports (ICSRs) and Published Case ReportsRosebraugh et al 2001;Strawn et al 2008, included in VigiBase dataset. Yoshikawa et al 2000Holtmann et al 2003;Hung et al 2009;Karakaya et al 2010, not included in VigiBase dataset Hanft et al 2004;Watson et al 2004,. included in VigiBase dataset, not retrieved from literature search.…”

mentioning

confidence: 99%

Rhabdomyolysis Reported for Children and Adolescents Treated with Antipsychotic Medicines: A Case Series Analysis

Star

Iessa

Almandil

et al. 2012

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

Monitoring of children and adolescents needs to be intensified during dose increases, or when a new, added, or switched antipsychotic medicine is introduced to their drug regimen, and during exposure to known risk factors for rhabdomyolysis. The development of seemingly nonserious events, such as abdominal pain, muscle pain, weakness, and dark urine, should be followed up during antipsychotic use, as they might be precursory events to rhabdomyolysis that eventually could develop into acute renal failure.

show abstract

Neuroleptic Malignant Syndrome in an Adolescent After Brief Exposure to Olanzapine

Cited by 4 publications

References 0 publications

Effects of risperidone on energy balance in female C57BL/6J mice

Effects of risperidone on energy balance in female C57BL/6J mice

Neuroleptic Malignant Syndrome Due to Risperidone Overdose in a Child: A Case Report

Rhabdomyolysis Reported for Children and Adolescents Treated with Antipsychotic Medicines: A Case Series Analysis

Contact Info

Product

Resources

About